Acumen Pharmaceuticals, Inc. (ABOS)
| Market Cap | 179.81M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -121.34M |
| Shares Out | 72.21M |
| EPS (ttm) | -2.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 133,534 |
| Open | 2.510 |
| Previous Close | 2.520 |
| Day's Range | 2.470 - 2.540 |
| 52-Week Range | 0.959 - 3.600 |
| Beta | 0.34 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+221.29%) |
| Earnings Date | May 12, 2026 |
About ABOS
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sa... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ABOS stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 221.29% from the latest price.
News
Acumen Pharmaceuticals Earnings Call Transcript: Q4 2025
Clinical and financial progress marked 2025, with ALTITUDE-AD phase II on track for late 2026 data and strong EBD preclinical results driving a $36M private placement. Cash reserves support operations into early 2027, and the pipeline is positioned for further growth.
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
NEWTON, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that...
Acumen Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum
Sabirnetug, a selective antibody for toxic Abeta oligomers, is in phase II trials for Alzheimer's, with late 2026 data expected to validate its efficacy and safety. Enhanced brain delivery programs and a JCR partnership aim to further improve outcomes, with clinical entry targeted for 2027.
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
NEWTON, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha...
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloi...
Acumen Pharmaceuticals Earnings Call Transcript: Q3 2025
Phase II ALTITUDE-AD trial for sabirnetug is progressing, with open-label extension underway and top-line results expected in late 2026. Cash reserves of $136.1 million support operations into early 2027, while the EBD program advances through a strategic partnership with JCR Pharmaceuticals.
Acumen Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference
Sabirnetug, a selective anti-oligomer antibody, is advancing in phase II for Alzheimer's, with promising biomarker and safety data from phase I. Strategic collaborations and innovative delivery approaches position the program for future growth, with key data expected next year.
Acumen Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025
Sabirnetug, a highly selective anti-amyloid-beta oligomer antibody, is advancing through a robust phase 2 trial in early Alzheimer's, with strong safety and biomarker data from phase 1. Strategic partnerships aim to enhance delivery and expand the pipeline, with key milestones expected in 2026.
Acumen Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference
Alzheimer's research is advancing with new disease-modifying therapies, innovative biomarker-driven diagnostics, and a focus on oligomer-directed antibodies. Subcutaneous formulations and enhanced brain delivery are in development, while combination and chronic treatment strategies are expected to shape the future landscape.
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...
Acumen Pharmaceuticals Earnings Call Transcript: Q2 2025
Q2 2025 saw strong operational progress, including full ALTITUDE-AD enrollment and a strategic JCR partnership for BBB-penetrating Alzheimer's therapies. Cash reserves of $166.2M support operations into 2027, with top-line ALTITUDE-AD results expected in late 2026.
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
NEWTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that ...
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
NEWTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that...
JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform
HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announ...
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid bet...
Acumen Pharmaceuticals Transcript: BofA Securities 2025 Healthcare Conference
Sabirnetug, a monoclonal antibody targeting amyloid beta oligomers, showed strong safety, robust biomarker engagement, and low ARIA rates in phase I. The phase II Altitude AD study rapidly enrolled 542 patients and will assess cognitive outcomes over 18 months.
Acumen Pharmaceuticals Earnings Call Transcript: Q1 2025
Enrollment for the phase II ALTITUDE-AD study was completed ahead of schedule, with top-line results expected in late 2026. Cash reserves of $197.9 million support operations into early 2027, and recent advances in biomarker screening have improved trial efficiency.
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloi...
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that ...
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from...
Acumen Pharmaceuticals Earnings Call Transcript: Q4 2024
Full enrollment of the ALTITUDE-AD phase II trial was achieved ahead of schedule, with top-line results expected in late 2026. Financially, the year ended with $231.5 million in cash, supporting operations into 2027, and a net loss of $102.3 million.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic tha...
Acumen Pharmaceuticals Transcript: Stifel’s 2025 Virtual CNS Forum
Sabirnetug, a novel oligomer-selective antibody for Alzheimer's, is advancing through a 540-patient phase II trial with promising phase I safety and biomarker data. Subcutaneous formulation results are imminent, and the company is well-funded through 2027.
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DN...